Genome-wide association analysis of age-at-onset in Alzheimer's disease.
Title | Genome-wide association analysis of age-at-onset in Alzheimer's disease. |
Publication Type | Journal Article |
Year of Publication | 2012 |
Authors | Kamboh, MI, Barmada, MM, Demirci, FY, Minster, RL, Carrasquillo, MM, Pankratz, VS, Younkin, SG, Saykin, AJ, Sweet, RA, Feingold, E, DeKosky, ST, Lopez, OL |
Corporate Authors | Alzheimer's Disease Neuroimaging Initiative |
Journal | Mol Psychiatry |
Volume | 17 |
Issue | 12 |
Pagination | 1340-6 |
Date Published | 2012 Dec |
ISSN | 1476-5578 |
Keywords | Age of Onset, Aged, Alzheimer Disease, Apolipoproteins E, Cadherins, European Continental Ancestry Group, Female, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Polymorphism, Single Nucleotide |
Abstract | The risk of Alzheimer's disease (AD) is strongly determined by genetic factors and recent genome-wide association studies (GWAS) have identified several genes for the disease risk. In addition to the disease risk, age-at-onset (AAO) of AD has also strong genetic component with an estimated heritability of 42%. Identification of AAO genes may help to understand the biological mechanisms that regulate the onset of the disease. Here we report the first GWAS focused on identifying genes for the AAO of AD. We performed a genome-wide meta-analysis on three samples comprising a total of 2222 AD cases. A total of ~2.5 million directly genotyped or imputed single-nucleotide polymorphisms (SNPs) were analyzed in relation to AAO of AD. As expected, the most significant associations were observed in the apolipoprotein E (APOE) region on chromosome 19 where several SNPs surpassed the conservative genome-wide significant threshold (P<5E-08). The most significant SNP outside the APOE region was located in the DCHS2 gene on chromosome 4q31.3 (rs1466662; P=4.95E-07). There were 19 additional significant SNPs in this region at P<1E-04 and the DCHS2 gene is expressed in the cerebral cortex and thus is a potential candidate for affecting AAO in AD. These findings need to be confirmed in additional well-powered samples. |
DOI | 10.1038/mp.2011.135 |
Alternate Journal | Mol. Psychiatry |
PubMed ID | 22005931 |
PubMed Central ID | PMC3262952 |
Grant List | K01 AG030514 / AG / NIA NIH HHS / United States R01 AG019771 / AG / NIA NIH HHS / United States P30 AG10133 / AG / NIA NIH HHS / United States P30 AG010133 / AG / NIA NIH HHS / United States U24 AG021886 / AG / NIA NIH HHS / United States P50 AG005133-28 / AG / NIA NIH HHS / United States U01 AG024904 / AG / NIA NIH HHS / United States R01 AG027224-05 / AG / NIA NIH HHS / United States RC2 AG036535 / AG / NIA NIH HHS / United States AG18023 / AG / NIA NIH HHS / United States R01 AG018023-05 / AG / NIA NIH HHS / United States AG030653 / AG / NIA NIH HHS / United States R01 AG030653-03 / AG / NIA NIH HHS / United States P50 AG005133 / AG / NIA NIH HHS / United States R01 AG19771 / AG / NIA NIH HHS / United States R01 AG030653 / AG / NIA NIH HHS / United States R01 AG027224 / AG / NIA NIH HHS / United States P30 AG010129 / AG / NIA NIH HHS / United States AG005133 / AG / NIA NIH HHS / United States R01 AG018023 / AG / NIA NIH HHS / United States AG027224 / AG / NIA NIH HHS / United States |